Mutation scanning of the RET protooncogene using high-resolution melting analysis

被引:35
作者
Margraf, RL
Mao, R
Highsmith, WE
Holtegaard, LM
Wittwer, CT
机构
[1] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA
[2] Mayo Clin Rochester, Mol Genet Lab, Rochester, MN USA
[3] ARUP, Inst Clin & Expt Pathol, Salt Lake City, UT USA
关键词
D O I
10.1373/clinchem.2005.052951
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Single-base pair missense mutations in exons 10, 11, 13, 14, 15, and 16 of the RET protooncogene are associated with the autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma. The current widely used approach for RET mutation detection is sequencing of the exons. Methods: Because RET mutations are rare and the majority are heterozygous mutations, we investigated RET mutation detection by high-resolution amplicon melting analysis. This mutation scanning technique uses a saturating double-stranded nucleic acid binding dye, LCGreen (R), and the high-resolution melter, HR-1 (TM), to detect heterozygous and homozygous sequence variations. Mutant genotypes are distinguished from the wild-type genotype by an altered amplicon melting curve shape or position. Results: Samples of 26 unique RET mutations, 4 nonpathogenic polymorphisms, or the wild-type genotype were available for this study. The developed RET mutation-scanning assay differentiated RET sequence variations from the wild-type genotype by altered derivative melting curve shape or position. A blinded study of 80 samples (derived from the 35 mutant, polymorphism, or wild-type samples) demonstrated that 100% of RET sequence variations were differentiated from wild-type samples. For exons 11 and 13, the nonpathogenic polymorphisms could be distinguished from the pathogenic RET mutations. Some RET mutations could be directly genotyped by the mutation scanning assay because of unique derivative melting curve shapes. Conclusion: RET high-resolution amplicon melting analysis is a sensitive, closed-tube assay that can detect RET protooncogene sequence variations. (c) 2006 American Associaton for Clinical Chemistry.
引用
收藏
页码:138 / 141
页数:4
相关论文
共 25 条
[1]  
Blank RD, 1996, CLIN CHEM, V42, P598
[2]   Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression [J].
Borrego, S ;
Sáez, ME ;
Ruiz, A ;
Gimm, O ;
López-Alonso, M ;
Antiñolo, G ;
Eng, C .
JOURNAL OF MEDICAL GENETICS, 1999, 36 (10) :771-774
[3]   PREDICTING DNA DUPLEX STABILITY FROM THE BASE SEQUENCE [J].
BRESLAUER, KJ ;
FRANK, R ;
BLOCKER, H ;
MARKY, LA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (11) :3746-3750
[4]  
CECCHERINI I, 1994, ONCOGENE, V9, P3025
[5]  
de la Fuente M, 2001, CLIN CHEM, V47, P1131
[6]   Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene [J].
Dobrowolski, SE ;
McKinney, JT ;
Filippo, CAS ;
Sim, KG ;
Wilcken, B ;
Longo, N .
HUMAN MUTATION, 2005, 25 (03) :306-313
[7]   RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population [J].
Elisei, R ;
Cosci, B ;
Romei, C ;
Bottici, V ;
Sculli, M ;
Lari, R ;
Barale, R ;
Pacini, F ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07) :3579-3584
[8]  
Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO
[9]  
2-Q
[10]  
Kambouris M, 1996, HUM MUTAT, V8, P64, DOI 10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.3.CO